Clinical trial · Observational
Post Mortem Tissue Donation of Pediatric Tumor Tissues and Cells
NCT05120518CI-TRIAL-00113408recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to utilize all donated pediatric tumor tissues and cells obtained from autopsy to prospectively develop novel patient derived orthotopic xenograft (PDOX) mouse models as well as in vitro cell culture model systems for pediatric cancers, and also provide tissue samples to other researchers and organizations (eg, CBTN, DIPG Registry, COG).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pediatric Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Collection of post mortem tissue donation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Pediatric patients with cancer and non-cancer tumor types
- description
- Pediatric patients with cancer and non-cancer tumor types (solid, liquid, neuro-oncology and stem cell)
- interventionNames
- Other: Collection of post mortem tissue donation
Primary outcomes (1)
- measure
- Procurement of pediatric cancer and non-cancer tumor tissue during autopsy with signed consent
- timeFrame
- Up to 5 years from procurement
- description
- Procurement of pediatric cancer and non-cancer tumor tissue during autopsy with signed consent. Tissue will be collected through a research tissue collection autopsy of the original tumor and other sites that are appropriate. Samples of both tumor and normal cells will be collected in addition to body fluids such as cerebrospinal fluid (CSF), blood, bone marrow, and skin biopsies for genomic testing.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Pediatric patients with cancer and non-cancer tumor types (solid, liquid, neuro-oncology) * Signed consent for post mortem tissue donation and autopsy Exclusion Criteria: * Signed consent for post mortem tissue donation and autopsy not obtained
References
Publications (5)
- BACKGROUNDBaker JN, Windham JA, Hinds PS, Gattuso JS, Mandrell B, Gajjar P, West NK, Hammarback T, Broniscer A. Bereaved parents' intentions and suggestions about research autopsies in children with lethal brain tumors. J Pediatr. 2013 Aug;163(2):581-6. doi: 10.1016/j.jpeds.2013.01.015. Epub 2013 Feb 19. PMID 23433673
- BACKGROUNDBroniscer A, Baker JN, Baker SJ, Chi SN, Geyer JR, Morris EB, Gajjar A. Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. Cancer. 2010 Oct 1;116(19):4632-7. doi: 10.1002/cncr.25405. PMID 20589749
- BACKGROUNDWiener L, Sweeney C, Baird K, Merchant MS, Warren KE, Corner GW, Roberts KE, Lichtenthal WG. What do parents want to know when considering autopsy for their child with cancer? J Pediatr Hematol Oncol. 2014 Aug;36(6):464-70. doi: 10.1097/MPH.0000000000000078. PMID 24309611
- BACKGROUNDAlabran JL, Hooper JE, Hill M, Smith SE, Spady KK, Davis LE, Peterson LS, Malempati S, Ryan CW, Acosta R, Spunt SL, Keller C. Overcoming autopsy barriers in pediatric cancer research. Pediatr Blood Cancer. 2013 Feb;60(2):204-9. doi: 10.1002/pbc.24320. Epub 2012 Sep 26. PMID 23015377
- BACKGROUNDMeeting Minutes: Enhancing Biobanking for Childhood Cancers, NCI, May 13, 2019